SRR8518426
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.650
- INTERFERON_GAMMA_RESPONSE+0.550
- PI3K_AKT_MTOR_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.330
- ALLOGRAFT_REJECTION+0.320
- MTORC1_SIGNALING+0.310
- COMPLEMENT+0.250
- TNFA_SIGNALING_VIA_NFKB+0.250
- ANDROGEN_RESPONSE+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- WNT_BETA_CATENIN_SIGNALING-0.280
- MYC_TARGETS_V2-0.240
- E2F_TARGETS-0.230
- NOTCH_SIGNALING-0.220
- APICAL_JUNCTION-0.170
- DNA_REPAIR-0.170
- UV_RESPONSE_DN-0.150
- MYOGENESIS-0.110
- ANGIOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclcWD9900_S48.txt | — | cohortA1 | 0.837 |
| 2 | SRR23036887 | — | — | 0.821 |
| 3 | 5ed0377f-26aa-4b4c-bb59-03001895aecd | — | — | 0.808 |
| 4 | SRR26320072 | — | — | 0.800 |
| 5 | 20030050.Her2HRneg | — | D | 0.799 |
| 6 | SRR8518287 | — | C | 0.796 |
| 7 | SRR23036886 | — | — | 0.793 |
| 8 | 20110002.Her2HRneg | — | D | 0.786 |
| 9 | TCGA-CQ-6223-01A-11R-1915-07 | — | — | 0.784 |
| 10 | SRR15069614 | — | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.650 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |